Europe Non Small Cell Lung Cancer Diagnostics Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2021 –2028 |
 Market Size (Base Year) |
USD 331.31 Million |
 Market Size (Forecast Year) |
USD 846.60 Million |
 CAGR |
% |
| Major Markets Players |
Europe Non-Small Cell Lung Cancer Diagnostics Market, By Cancer Type (Lung Adenocarcinoma (LUAD), Lung Squamous Cell Carcinoma (LUSC), Large Cell Carcinoma And Others), Product (Reagents And Kits, Instruments, And Services And Software’s) Test(Imaging Test, Molecular Test, Biopsy, Sputum Cytology, Thoracentesis, Immunohistochemistry, And Others), End-User (Hospital, Clinical Laboratories, Academics And Others) Country (France, Russia, Netherlands, U.K., Germany, Italy, Spain, Turkey, Belgium, Switzerland and Rest of Europe) Industry Trends and Forecast to 2028.
Market Analysis and Insights: Europe Non-Small Cell Lung Cancer Diagnostics Market
Europe non-small cell lung cancer diagnostics market is expected to reach USD 846.60 million by 2028 from USD 331.31 million in 2020, growing at a steady CAGR of 12.5% in the forecast period of 2021 to 2028.
Non-small cell lung cancer is a disease in which malignant cells or cancer cells are formed in the tissues of the lungs. These are of different types, and each type has different cancer cells that grow and spread in different ways. The non-small cell lung cancer (NSCLC) types are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. In squamous cell carcinoma, the cancer forms in the thin, flat cells lining inside the lungs and is called epidermoid carcinoma. Large cell carcinoma cancer begins in several types of large cells. The adenocarcinoma type of cancer begins in the cells that line the alveoli and make substances such as mucus. One of the significant risks for non-small cell lung cancer (NSCLC) is that smoking and symptoms include a cough that doesn't go away and shortness of breath. Various tests are used, such as imaging tests, molecular tests, biopsies, and others, to diagnose and examine the cancer stage. Diagnosis is essential to identify the disease in time so that proper treatment could be given to patients.
The factors driving the growth of the non-small cell lung cancer diagnostics market are the usage of artificial intelligence and machine learning to improve the diagnostics procedures coupled with the rise in the number of geriatric population that is more susceptible to non-small cell lung cancer while high competition in the market and disturbed supply chain due to the COVID-19 pandemic may challenge the non-small cell lung cancer diagnostics market growth.
Furthermore, the rise in healthcare expenditure in developing countries and the increase in the adoption of new technology to diagnose non-small cell lung cancer will create huge opportunities for the global non-small cell lung cancer diagnostics market. On the other hand, the high competition in the market and disturbed supply chain due to the COVID-19 pandemic are expected to challenge the global non-small cell lung cancer diagnostics market.
The non-small cell lung cancer diagnostics market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the non-small cell lung cancer diagnostics market scenario, contact Data Bridge Market Research for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.
Europe Non-Small Cell Lung Cancer Diagnostics Market Scope and Market Size
The Europe non-small cell lung cancer diagnostics market is segmented into four notable segments based on the cancer type, products, test, and end-user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of cancer type, the Europe non-small cell lung cancer diagnostics market is segmented into lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), large cell carcinoma, and others. In 2021, the lung adenocarcinoma (LUAD) segment is expected to dominate the non-small cell lung cancer diagnostics market due to the increase in the number of adenocarcinoma lung cancer cases all around the world.
- On the basis of products, the Europe non-small cell lung cancer diagnostics market is segmented into reagents and kits, instruments and services, and software. In 2021, the instrument is expected to dominate the non-small cell lung cancer diagnostics market due to the increasing need for lung cancer diagnostics instruments to diagnose the disease on time.
- On the basis of the test, the Europe non-small cell lung cancer diagnostics market is segmented into imaging tests, molecular tests, biopsy, sputum cytology, thoracentesis, immunohistochemistry, and others. In 2021, the molecular test segment is expected to dominate the non-small cell lung cancer diagnostics market due to the rising need for a molecular test to diagnose lung cancer disease properly and with high accuracy.
- On the basis of end-user, the Europe non-small cell lung cancer diagnostics market is segmented into hospitals, clinical laboratories, academics, and others. In 2021, the clinical laboratories segment is expected to dominate the non-small cell lung cancer diagnostics market due to the growing need for non-small cell lung cancer diagnostics in clinical laboratories.
Europe Non-Small Cell Lung Cancer Diagnostics Market: Country Level Analysis
Europe non-small cell lung cancer diagnostics market is segmented into four notable segments based on the cancer type, products, test, and end-user.
Countries covered in the Europe Non-small cell lung cancer diagnostics market report are France, Russia, Netherlands, U.K., Germany, Italy, Spain, Turkey, Belgium, Switzerland, and the rest of Europe.
The products segment in the France region is expected to grow with the highest CAGR in the forecast period of 2021 to 2028 because of the increase in demand for diagnosis instruments to diagnose non-small cell lung cancer patients. Germany is expected to dominate the Europe non-small cell lung cancer diagnostics market with the highest market share owing to increased healthcare expenditure. Italy is expected to lead the growth of the Europe non-small cell lung cancer diagnostics market for products segment is dominating in this country due to rising healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of European brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities By Major Market Players To Enhance The Awareness For Non-Small Cell Lung Cancer Diagnostics, Is Boosting The Market Growth Of Non-Small Cell Lung Cancer Diagnostics Market.
The non-small cell lung cancer diagnostics market also provides you with a detailed market analysis for every country's growth in a particular market. Additionally, it provides detailed information regarding the market players' strategy and their geographical presence. The data is available for the historical period 2010 to 2019.
Competitive Landscape And Europe Non-Small Cell Lung Cancer Diagnostics Market Share Analysis
Europe non-small cell lung cancer diagnostics market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, India presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the companies' focus related to the non-small cell lung cancer diagnostics market.
Some of the major players operating in the non-small cell lung cancer diagnostics market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString, Janssen Pharmaceutical NV, Inivata Ltd, bioMérieux SA, OncoCyte Corporation Inc., GENERAL ELECTRIC COMPANY, Eckert & Ziegler, Dr. Lal PathLabs, RIVERAIN TECHNOLOGIES, Oncimmune, among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many contracts, agreements, and launches are also initiated by the companies worldwide, which are also accelerating the non-small cell lung cancer diagnostics market.
For instance,
- In March 2021, Agilent Technologies, Inc. acquired Resolution Bioscience for USD 550 million to strengthen its business in next-generation sequencing (NGS)-based oncology solutions
- In May 2021, QIAGEN launched FDA approved therascreen KRAS RGQ PCR Kit, which aids in the identification of non-small cell lung cancer (NSCLC) in patients
- In June 2020, F. Hoffmann-La Roche Ltd launched an automated digital pathology algorithm, uPath PD-L1 (SP263) image analysis, to diagnose non-small cell lung cancer (NSCLC) and improve the speed and accuracy of diagnosis treatment
Collaboration, product launch, business expansion, award and recognition, joint ventures, and other strategies by the market player are enhancing the company's footprints in the non-small cell lung cancer diagnostics market, which also provides the benefit for the organization's profit growth.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 CANCER TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ROLE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING
4.2 PRODUCT AND BRAND ANALYSIS: EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET
4.3 ABBOTT LABORATORIES-
4.4 F. HOFFMANN-LA ROCHE LTD -
4.5 AGILENT TECHNOLOGIES, INC.
4.6 QIAGEN
4.7 THERMO FISHER SCIENTIFIC, INC
4.8 QUEST DIAGNOSTICS INCORPORATED
4.9 NEOGENOMICS LABORATORIES, INC.
4.1 NANOSTRING
4.11 JANSSEN PHARMACEUTICAL NV
4.12 INIVATA LTD
4.13 BIOMÉRIEUX SA
4.14 BIOTHERANOSTICS, INC.
4.15 ONCOCYTE CORPORATION
4.16 ECKERT & ZIEGLER
4.17 GENERAL ELECTRIC COMPANY
4.18 DR LAL PATHLABS
4.19 RIVERAIN TECHNOLOGIES
4.2 PLEXBIO CO.,LTD
4.21 BIODESIX
4.22 ONCIMMUNE
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISE IN PREVALENCE OF LUNG CANCER ACROSS THE WORLD
5.1.2 GROWING NUMBER OF GERIATRIC POPULATION THAT IS MORE SUSCEPTIBLE TO NON-SMALL CELL LUNG CANCER
5.1.3 GROWING COLLABORATION PARTNERSHIP AND AGREEMENT BY THE KEY PLAYERS
5.1.4 GROWING USAGE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING TO IMPROVE THE DIAGNOSTIC PROCEDURES
5.1.5 INCREASING PREVALENCE OF UNHEALTHY LIFESTYLE THAT POSES A SERIOUS RISK OF LUNG CANCER
5.1.6 GROWING PRODUCT LAUNCHES
5.2 RESTRAINTS
5.2.1 CHALLENGES ASSOCIATED WITH BRAND EQUITY
5.2.2 MAINTAINING HIGH LEVEL OF EXPERTISE FOR DIAGNOSIS PURPOSE
5.3 OPPORTUNITIES
5.3.1 RISING HEALTHCARE EXPENDITURE IN DEVELOPING REGION
5.3.2 INCREASING ADOPTION OF NEW TECHNOLOGY TO DIAGNOSE NON-SMALL CELL LUNG CANCER
5.3.3 INCREASE IN THE NUMBER OF APPROVALS FOR NON-SMALL CELL LUNG CANCER PRODUCTS
5.4 CHALLENGES
5.4.1 HIGH COMPETITION AMONG MARKET PLAYERS
5.4.2 DISTURBED SUPPLY CHAIN DUE TO COVID-19
6 IMPACT OF COVID-19 ON THE EUROPE NON SMALL CELL LUNG CANCER DIAGNOSTIC MARKET
6.1 IMPACT ON DEMAND
6.2 IMPACT ON SUPPLY CHAIN
6.3 IMPACT ON PRICE
6.4 CONCLUSION
7 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE
7.1 OVERVIEW
7.2 LUNG ADENOCARCINOMA (LUAD)
7.3 LUNG SQUAMOUS CELL CARCINOMA (LUSC)
7.4 LARGE CELL CARCINOMA
7.5 OTHERS
8 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 INSTRUMENTS
8.3 REAGENTS AND KITS
8.3.1 LUNG CANCER ASSAY KIT
8.3.2 MUTATION KIT
8.3.3 EXTRACTION KIT
8.3.4 SAMPLE PREPARATION KIT
8.3.5 SOLID TUMOUR KIT
8.3.6 OTHERS
8.4 SERVICES AND SOFTWARES
9 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST
9.1 OVERVIEW
9.2 MOLECULAR TEST
9.2.1 RT-PCR
9.2.2 NEXT-GENERATION SEQUENCING (NGS)
9.2.3 DNA MICROARRAY
9.2.4 NEXT GENERATION CAPTURE
9.2.5 LAB-ON -A CHIP (LOAC)
9.2.6 MULTIPLEX CONVENTIONAL
9.2.7 PROTEIN MICROARRAY
9.2.8 OTHER
9.3 IMAGING TEST
9.3.1 PISITRON EMISSION TOMOGRAPHY (PET) SCAN
9.3.2 MAGNETIC RESONANCE IMAGING (MRI) SCAN
9.3.3 CT SCAN
9.3.4 BONE SCAN
9.3.5 OTHERS
9.4 IMMUNOHISTOCHEMISTRY
9.5 BIOPSY
9.6 SPUTUM CYTOLOGY
9.7 THORECENTESIS
9.8 OTHERS
10 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER
10.1 OVERVIEW
10.2 CLINICAL LABORATORIES
10.3 HOSPITAL
10.4 ACADEMICS
10.5 INSTITUTES AND RESEARCH CENTERS
11 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION
11.1 EUROPE
11.1.1 GERMANY
11.1.2 FRANCE
11.1.3 ITALY
11.1.4 RUSSIA
11.1.5 U.K.
11.1.6 SPAIN
11.1.7 TURKEY
11.1.8 SWITZERLAND
11.1.9 BELGIUM
11.1.10 NETHERLANDS
11.1.11 REST OF EUROPE
12 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 ABBOTT LABORATORIES
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 F. HOFFMANN-LA ROCHE LTD
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 QUEST DIAGNOSTICS INCORPORATED
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 GENERAL ELECTRIC COMPANY
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 NANOSTRING
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 AGILENT TECHNOLOGIES, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 BIODESIX
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 BIOMERIEUX SA
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 BIOTHERANOSTICS
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 DR LAL PATHLABS
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 ECKERT & ZIEGLER
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 INIVATA LTD
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 JANSSEN PHARMACEUTICAL NV
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 NEOGENOMICS LABORATORIES, INC.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 ONCIMMUNE
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 ONCOCYTE CORPORATION
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
14.17 PLEXIBIO CO LTD
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 QIAGEN
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENTS
14.19 RIVERAIN TECHNOLOGIES
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 THERMO FISHER SCIENTIFIC INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
List of Table
LIST OF TABLES
TABLE 1 AGING WORLD POPULATION
TABLE 2 U.K. X RAY DEMAND 2018
TABLE 3 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 4 EUROPE LUNG ADENOCARCINOMA (LUAD) IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 EUROPE LUNG SQUAMOUS CELL CARCINOMA (LUSC) IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 EUROPE LARGE CELL CARCINOMA IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 EUROPE OTHERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 9 EUROPE INSTRUMENTS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 EUROPE REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 EUROPE REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 12 EUROPE SERVICES AND SOFTWARES IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 14 EUROPE MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 EUROPE MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 16 EUROPE IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 EUROPE IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 18 EUROPE IMMUNOHISTOCHEMISTRY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 EUROPE BIOPSY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2020
TABLE 20 EUROPE SPUTUM CYTOLOGY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 EUROPE THORECENTESIS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 EUROPE OTHERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 24 EUROPE CLINICAL LABORATORIES IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 EUROPE HOSPITAL IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 EUROPE ACADEMICS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 EUROPE INSTITUTES AND RESEARCH CENTERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 29 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 30 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 31 EUROPE REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 32 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 33 EUROPE IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 34 EUROPE MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 35 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 36 GERMANY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 37 GERMANY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 38 GERMANY REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 39 GERMANY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 40 GERMANY IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 41 GERMANY MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 42 GERMANY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 43 FRANCE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 44 FRANCE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 45 FRANCE REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 46 FRANCE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 47 FRANCE IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 48 FRANCE MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 49 FRANCE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 50 ITALY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 51 ITALY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 52 ITALY REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 53 ITALY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 54 ITALY IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 55 ITALY MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 56 ITALY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 57 RUSSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 58 RUSSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 59 RUSSIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 60 RUSSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 61 RUSSIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 62 RUSSIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 63 RUSSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 64 U.K. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 65 U.K. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 66 U.K. REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 67 U.K. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 68 U.K. IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 69 U.K. MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 70 U.K. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 71 SPAIN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 72 SPAIN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 73 SPAIN REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 74 SPAIN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 75 SPAIN IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 76 SPAIN MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 77 SPAIN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 78 TURKEY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 79 TURKEY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 80 TURKEY REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 81 TURKEY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 82 TURKEY IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 83 TURKEY MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 84 TURKEY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 85 SWITZERLAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 86 SWITZERLAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 87 SWITZERLAND REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 88 SWITZERLAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 89 SWITZERLAND IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 90 SWITZERLAND MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 91 SWITZERLAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 92 BELGIUM NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 93 BELGIUM NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 94 BELGIUM REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 95 BELGIUM NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 96 BELGIUM IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 97 BELGIUM MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 98 BELGIUM NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 NETHERLANDS NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 100 NETHERLANDS NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 101 NETHERLANDS REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 102 NETHERLANDS NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 103 NETHERLANDS IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 104 NETHERLANDS MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 105 NETHERLANDS NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 106 REST OF EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
List of Figure
LIST OF FIGURES
FIGURE 1 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 10 RISE IN THE GERIATRIC POPULATION THAT IS MORE SUSCEPTIBLE TO NON-SMALL CELL LUNG CANCER IS EXPECTED TO DRIVE THE EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET IN 2021 & 2028
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET
FIGURE 13 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2020
FIGURE 14 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020
FIGURE 15 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2020
FIGURE 16 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2020
FIGURE 17 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2020)
FIGURE 18 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020)
FIGURE 19 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 20 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 21 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY LUNG CANCER TYPE (2021 & 2028)
FIGURE 22 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
